Gilead Sciences (GILD) Common Equity (2009 - 2026)

Gilead Sciences has reported Common Equity for 18 years, with the latest figure at $23.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 23.26% year-over-year to $23.5 billion; the trailing twelve-month figure through Mar 2026 stood at $23.5 billion (up 23.26% YoY), and the FY2025 full-year result was $22.7 billion, up 17.96% from the prior year.
• Common Equity for Q1 2026 stood at $23.5 billion, up from $22.7 billion in the prior quarter.
• The five-year high for Common Equity was $23.5 billion in Q1 2026, with the low at $17.5 billion in Q1 2024.
• Historically, Common Equity has averaged $20.5 billion across 5 years, with a median of $20.9 billion in 2023.
• Annual changes were most pronounced in 2024 — Common Equity fell 17.32% — and 2026, when it rose 23.26%.
• Gilead Sciences' Common Equity stood at $21.2 billion in 2022, then advanced by 7.26% to $22.7 billion in 2023, then fell by 15.4% to $19.2 billion in 2024, then increased by 17.96% to $22.7 billion in 2025, then increased by 3.58% to $23.5 billion in 2026.
• The last three Common Equity figures came in at $23.5 billion (Q1 2026), $22.7 billion (Q4 2025), and $21.5 billion (Q3 2025), per Business Quant data.